PTH and Miyoshi myopathy: Since signaling through the PTH1R in the osteoblast lineage regulates bone marrow hematopoietic niches, Pennisi et al. examined whether treating MM with an osteoblast-activating agent, intermittent PTH, could simultaneously help control bone disease and myeloma cell growth [60].